Table 2. Cancer cell lines expressing increased genomic Usmg5 copy number in Oncomine cancer genomics database and Cancer Cell Line Encyclopedia, CCLE.
Classification | Cancer type | Cell line | DNA copy number | Oncomine dataset/ CCLE |
---|---|---|---|---|
Bone | Osteosarcoma | 143B | 2,76 | CCLE [31] |
Brain | Brain gioblastoma | A-172 | 3,48 | Berouchim brain [35] |
Cerebral glioblastoma | LN-18 | 2,78 | Berouchim brain [35] | |
Breast | Breast adenocarcinoma | MCF7 | 2,62 | Nicolsky Breast [32] |
Breast carcinoma | SUM-52PE | 3,60 3,42 |
Nicolsky Breast [32] Chin breast2 [65] |
|
CAL-51 | 3,28 | Hu CellLine2 [66] | ||
MDA-MB-468 | 2,96 | Hu CellLine2 [66] | ||
CAL-120 | 2,81 | Hu CellLine2 [66] | ||
Hs 578T | 2,74 | Hu CellLine2 [66] | ||
MDA-MB-361 | 2,72 | Hu CellLine2 [66] | ||
HCC1806 | 2,62 | CCLE [31] | ||
Ductal breast carcinoma | T-47D | 3,18 | Nicolsky Breast [32] | |
MFM-223 | 2,85 | Nicolsky Breast [32] | ||
Squamous cell breast carcinoma, Acantholytic variant | HCC1806 | 2,88 | Hu CellLine2 [66] | |
Central nervous system | Cannabinoid receptor | CB1 | 2,69 | CCLE [31] |
Glioma | KSN60 | 2,59 | CCLE [31] | |
Endometrium | Endometrial adenocarcinoma | JHUEM2 | 2,60 | CCLE [31] |
AN3CA | 2,60 2,59 |
CCLE [31] Rothenberg CellLine [38] |
||
Esophagus | Eesophageal adenocarcinoma | JHESOAD1 | 2,61 | CCLE [31] |
Barrett's adenocarcinoma | OE33 | 2,77 2,65 |
CCLE [31] Wooster CellLine [N/A] |
|
Gallbladder | Biliary tract cancer | SNU478 | 3,49 | CCLE [31] |
Gastric | Cecum adenocarcinoma | LS411N | 2,70 | Lu colorectal [67] |
NCI-H498 | 2,61 | Lu colorectal [67] | ||
NCI-H747 | 2,60 | Lu colorectal [67] | ||
Colon adenocarcinoma | SW620 | 2,88 | Lu colorectal [67] | |
HCT-15 | 2,77 | Lu colorectal [67] | ||
LS180 | 2,72 | Lu colorectal [67] | ||
Colon carcinoma | HCT116 | 2,94 2,78 2,78 2,77 |
CCLE [31] Berouchim multicancer [34] Lu colorectal [67] Rothenberg CellLine [38] |
|
Gastric cancer | Hs 746T | 3,54 2,90 |
Rothenberg CellLine [38] Palanisamy gastric [N/A] |
|
NCI-N87 | 3,41 | Palanisamy gastric [N/A] | ||
KATO111 | 3,34 | Palanisamy gastric [N/A] | ||
YCC-16 | 3,21 | Palanisamy gastric [N/A] | ||
HUG1N | 3,02 | CCLE [31] | ||
YCC-9 | 3,00 | Palanisamy gastric [N/A] | ||
YCC-6 | 2,85 | Palanisamy gastric [N/A] | ||
SNU520 | 2,69 | CCLE [31] | ||
Gastric tubular adenocarcinoma | MKN74 | 2,74 2,57 |
CCLE [31] Rothenberg CellLine [38] |
|
Gastrointestinal stromal tumor | GIST 882X | 2,97 | Berouchim multicancer [34] | |
Signet ring cell gastric adenocarcinoma | SNU-668 | 2,93 2,80 |
CCLE [31] Barretina CellLine 2 [31] |
|
Hematopoietic tissue | Acute Myeloid Leukemia | CMK115 | 2,90 | CCLE [31] |
KASUMI1 | 2,85 | CCLE [31] | ||
CMK | 2,67 | CCLE [31] | ||
M2-type of Myeloid Leukemia | KASUMI6 | 2,78 | CCLE [31] | |
Blast phase cronic myelogenous leukemia | MOLM6 | 2,78 2,60 |
CCLE [31] Barretina CellLine 2 [31] |
|
Chronic myeloid leukemia | BV173 | 2,55 | CCLE [31] | |
Leukemia | NCO2 | 2,53 | CCLE [31] | |
Erythroleukemia | TF-1 | 2,60 | Barretina CellLine 2 [31] | |
Kidney | Clear cell renal carcinoma | SNU-1272 | 3,13 2,77 |
CCLE [31] Barretina CellLine 2 [31] |
Renal carcinoma | UOK101 | 2,87 | CCLE [31] | |
Human proximal tubular cell line, immortalized | HK2 | 2,67 | CCLE [31] | |
Renal adenocarcinoma | ACHN | 2,55 | CCLE [31] | |
Liver | Hepatocellular adenocarcinoma | SNU-398 | 2,84 2,75 2,72 2,59 |
CCLE [31] Rothenberg CellLine [38] Wooster CellLine [N/A] Barretina CellLine 2 [31] |
Hepatocellular carcinoma | LI7 | 3,40 | CCLE [31] | |
C3A | 2,62 | CCLE [31] | ||
Lung | Lung adenocarcinoma | NCI-HI435 | 3,15 | CCLE [31] |
NCI-H1775 | 2,73 2,62 |
CCLE [31] Lu lung [67] |
||
NCI-H1993 | 2,79 2,72 2,62 |
Lu lung [67] Sos CellLine [69] Wooster CellLine [N/A] |
||
NCI-H1563 | 2,74 2,68 |
CCLE [31] Lu lung [67] |
||
NCI-H1838 | 2,63 | Lu lung [67] | ||
NCI-H1755 | 2,86 2,58 |
Sos CellLine [69] Rothenberg CellLine [38] |
||
VMRC-LCD | 2,67 2,57 |
CCLE [31] Rothenberg CellLine [38] |
||
LU65A | 2,75 | Rothenberg CellLine [38] | ||
Large cell lung carcinoma | Calu-6 | 2,59 | Lu lung [67] | |
Giant cell lung carcinoma | LU65B | 3,03 | Rothenberg CellLine [38] | |
Small cell lung carcinoma | NCI-H510 | 2,83 | CCLE [31] | |
DMS53 | 2,69 | Olejniczak CellLine 2 [68] | ||
SBC-5 | 2,69 2,64 |
CCLE [31] Rothenberg CellLine [38] |
||
DMS114 | 2,55 | CCLE [31] | ||
Non-small cell lung carcinoma | NCI-H1581 | 2,67 | CCLE [31] | |
Squamous cell lung carcinoma | HCC1897 | 3,53 | CCLE [31] | |
NCI-HI703 | 2,63 2,61 |
CCLE [31] Wooster CellLine [N/A] |
||
Lung carcinoma | EPLC272H | 2,56 | CCLE [31] | |
Lymphoid tissue | Anaplastic large cell lymphoma | Ki-JK | 3,21 2,80 |
CCLE [31] Barretina CellLine 2 [31] |
Non-Hodking B cell Lymphoma | JM1 | 2,79 | CCLE [31] | |
Non-Hodking T cell Lymphoma | SR786 | 2,78 | CCLE [31] | |
SUDHL1 | 2,65 | CCLE [31] | ||
Splenic marginal zone B-cell lymphoma | SLVL | 2,63 | Rothenberg CellLine [38] | |
Ovarian | Ovarian adenocarcinoma | TOV21G | 2,98 | CCLE [31] |
OVK18 | 2,89 | CCLE [31] | ||
CAO V3 | 2,62 | CCLE [31] | ||
Ovarian clear cell adenocarcinoma | OVTOKO | 4,04 3,20 |
CCLE [31] Barretina CellLine 2 [31] |
|
Ovarian mucinous custadenocarcinoma | MCAS | 3,05 2,92 2,68 |
CCLE [31] Rothenberg CellLine [38] Barretina CellLine 2 [31] |
|
Ovarian carcinoma | OVSAHO | 2,72 | CCLE [31] | |
Ovarian carcinoma | OVK12 | 2,65 | Barretina CellLine 2 [31] | |
Ovarian granulosa cell tumor | COV434 | 2,80 | CCLE [31] | |
Pancreas | Ampulla of Vater adenocarcinoma | SNU-478 | 3,08 | Barretina CellLine 2 [31] |
Pancreatic adenocarcinoma | PSN1 | 2,75 2,61 |
CCLE [31] Barretina CellLine 2 [31] |
|
PANC1 | 2,64 2,53 |
CCLE [31] Barretina CellLine2 [31] |
||
PK1 | 2,53 | CCLE [31] | ||
Panreatic carcinoma | PK45H | 2,63 | CCLE [31] | |
YAPC | 2,62 | CCLE [31] | ||
Skin | Cutaneous melanoma | A7 | 2,81 | Wooster CellLine [N/A] |
Melanoma | IGR1 | 2,63 | CCLE [31] | |
Squamous cell adenocarcinoma | HCC95 | 2,78 | Sos CellLine [69] | |
HCC-15 | 2,59 | Sos CellLine [69] | ||
Thyroid | Follicular thyroid carcinoma | ML1 | 2,53 | CCLE [31] |
N/A indicating not available